SABCS 2024

More testing - more surgery?

To Omit or Not to Omit: Rethinking SNL Biopsy

Practice changing combinations, treatment beyond progression and the art of medicine

Challenging the first line treatment and chemotherapy - what is our first line treatment of choice in the future?

CDK4/6i and ADC therapy for HER2+ and many more ADC options to come!

FASCINATE-N – GS1-04

PATINA – GS2-12

Ambivalent feelings about immunotherapy, but reassuring data for BRCA testing!

GeparDouze – GS3-05

CamRelief – GS3-06

OlympiA GS1-09

New data on CDK4/6i, oral SERDs and combinations, and evaluations

RW OS CDK4/6i – PS2-03

EMBER-3 – GS1-01

ADAPT – GS3-04

Time to limit postmastectomy radiotherapy indications

Risk reducing mastectomy in patients with BRCA mutation

ctDNA in follow-up - not for everyday clinical practice, but for clinical trials

The beginning of the end of sentinel lymph nodes

My highlights of SABCS 2024

From the ZEST study to the german SURVIVE study

Exciting updates on OlympiA

No axillary surgery necessary in selected patients

Olaparib after (neo)adjuvant chemotherapy

Survival benefit for patients with risk-reducing surgery

Who need anthracyclines for node-negative HR+ BC

Older EBC patients should also undergo surgery

BRCA-mut population - impact of surgery & OlympiA - update analysis

Phase 2 neoadjuvant study with HER3 DXd

Who needs chemotherapy?

Targets are important in EBC

Fine-tuning of chemotherapy in node-negative luminal HR+/HER2- patients

Equivalence to chemotherapy with the combination of anti-HER2+, ET and palbociclib

Neo-adjuvant monitoring with MRT & US can reduce therapy duration

Fascinating data from Shanghai

Is Margetuximab better than trastuzumab?

Atezolizumab does not improve EFS in TNBC

KEYNOTE-522 Interim analysis 4: Biomarkers

Biomarker analysis from the A-Brave trial

Jaka chemioterapia u chorych na raki ER+/HER2- bez zajęcia węzłów chłonnych?

Czas na ograniczenie wskazań do radioterapii po mastektomii

Equivalencia a la quimioterapia con la combinación de anti-HER2+, ET y palbociclib

OlympiA

Étude de phase 2 néoadjuvante avec HER3 DXd

Analisi dei biomarcatori nello studio A-Brave

I miei punti di forza di SABCS 2024

I bersagli sono importanti nella EBC

Population BRCA-mut - impact de la chirurgie & OlympiA - analyse actualisée

Studio neoadiuvante di fase 2 con HER3 DXd

EMBER-3

Targeting endocrine pathways is superior to Chemo in high-risk MBC patients

New SERD in phase-3-trial & CDK4/6 inhibitor in HR+ MBC

Abstract Nr. 1: Imlunestrant

CDK4/6i more equal than not

CDK4/6 inhibitor + ET is the best start for HR+ Patients

Efficacy data of EMBER-3

Comparison of all CDK4/6 in combination with AI in the US Real-Word Setting

Optimizing 1st line treatment with T-DXd followed HP in HER2+ mBC

Practice changing results for ER+/HER2+ patients

HER2DX might optimize 1st line in HER2+ mBC

CDK4/6 inhibitors effective also in luminal HER2+ cancers

DESTINY-Breast 12: Quality of life

Significant and clinical relevant benefit of the addition of palbociclib as maintenance therapy in ER+ / HER2+ ABC

CDK4/6 inhibitor in HER2+ metastatic BC

Il targeting delle vie endocrine è superiore alla CT nelle pazienti MBC ad alto rischio

Nouveau SERD en phase 3 d'essai & Inhibiteur CDK4/6 dans le MBC HR+

Inhibitory CDK4/6 skuteczne również w rakach luminalnych HER2+

Beneficio significativo y clínicamente relevante de la adición de palbociclib como terapia de mantenimiento en ER+ / HER2+ ABC

Optimización del tratamiento de 1ª línea con T-DXd seguido de HP en CMM HER2+.

Dati di efficacia di EMBER-3

HER2DX podría optimizar la 1ª línea en el CMM HER2+.